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Abstract
Background—Human immunodeficiency virus/acquired immunodeficiency disease syndrome-
associated mortality contributes considerably to overall mortality rates among adults in the United
States. The purpose of this review is to systematically examine conceptual approaches that have
been used to evaluate the association between socioeconomic status of people infected with human
immunodeficiency virus and their survival and summarize existing evidence regarding the
association between socioeconomic status and mortality due to human immunodeficiency virus/
acquired immunodeficiency disease syndrome.
Methods—We systematically retrieved neighborhood and individual-level studies of acquired
immunodeficiency disease syndrome-related or all-cause mortality among patients diagnosed with
human immunodeficiency virus that reported original data and analyzed socioeconomic status as a
predictor of mortality.
Results—We included 21 studies (19 cohort and 2 case-control studies). Heterogeneity in both
the conceptual approaches to socioeconomic status measurements and selection of variables for
the adjustment of the measure of association precluded meta-analysis of the results. Six studies
observing populations before the introduction of highly active antiretroviral therapy found that
socioeconomic status was not associated with human immunodeficiency virus/acquired
immunodeficiency disease syndrome mortality. In the post- highly active antiretroviral therapy
period socioeconomic status was inconsistently associated with Human immunodeficiency virus/
acquired immunodeficiency disease syndrome mortality risk in studies adjusting for highly active
antiretroviral therapy use.
Conclusion—Further studies considering multilevel socioeconomic status measurements and
controlling for treatment and clinical variables are needed to enhance understanding of the role of
socioeconomic gradients on human immunodeficiency virus outcomes.
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Introduction
Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)
remains an important public health problem despite significant worldwide efforts to combat
the disease. The availability of highly active antiretroviral therapy (HAART) in the United
States (US) and other developed countries altered the progression of HIV infection and
brought about a dramatic decline in mortality due to HIV/AIDS [1–4], increased the median
age at death due to HIV [5], and improved life expectancy after HIV diagnosis [6].
However, the rates of decline in HIV/AIDS morbidity and mortality have flattened in recent
years among all racial/ethnic groups [7,8]. By the end of 2009, an estimated 1,108,611
people developed AIDS in the US, and of those, over half have died [9]. Even though
survival has increased markedly, HIV/AIDS continues to be one of the major causes of
premature mortality in the US and young minority populations have been particularly
affected. In 2007, it was the fourth leading cause of death for non-Hispanic black (NHB)
males and third for NHB females aged 25–44 years, ranking higher than their respective
counterparts in other racial/ethnic groups (CDC, 2010) [10–12]. Therefore, for certain
groups, HIV-related mortality continues to be a particularly acute public health problem.
Early HIV testing [13–16], access to specialized care [17], and adherence to HAART [18–
20] are critical for control of disease progression. Yet, explanation of evident racial/ethnic
disparities in HIV/AIDS patterns requires looking at complex characteristics. Population
mobility, migration, and urbanization modify interactions between susceptible and infected
persons in populations [21]. In addition, broad challenges involving economic and social
deprivation, socialization patterns, socially inflicted trauma, targeted marketing of illicit
drugs, and limited access to health care may explain differences in health outcomes [22].
The facts that are nearly 1 in 4 NHBs live in poverty in the US and that the poverty rate for
NHBs remains about three times that of non-Hispanic whites (NHW) may partly explain the
racial/ethnic variations in the national rates of HIV/AIDS incidence [23–25]. Studies
observing associations between socioeconomic status and incidence of HIV/AIDS have
illustrated that problems related to poverty, including limited access to quality care; the
exchange of sex for drugs, money, or to meet other needs; and increased levels of substance
use can directly or indirectly increase HIV risk factors [26,27]. Queries whether the social
and economic situations of HIV-infected individuals explain variations in the disease
progression and survival are supported by the framework of social production of disease and
political economy of health. According to this framework, a person’s relative social and
economic positioning shapes behavior, and the relationship between subordinate-dominant
groups affects patterns of disease through material and social inequalities [28].
To date, research examining the role of SES on HIV/AIDS mortality has been scarce. In
addition to the difficulty of obtaining estimates of individual-level socioeconomic measures,
the limited research could be due to measurement problems arising from the lack of
conceptual clarity about the essential nature of social stratification and the absence of the
application of sound measurement theory to the construction of socioeconomic measures in
relation to health outcomes [29]. Socioeconomic status (SES) describing a person’s position
in a society is a multidimensional construct [29], but due to limited resources, most health
studies measure SES using a single socioeconomic variable measured at a single time point
and level [30]. This may be particularly restrictive in studies of HIV infection because
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socioeconomic factors affecting health of HIV-infected patients change not only at different
times in the life course [31], but also in the course of the disease through different causal
pathways [32,33].
The present review aims to explore the conceptual approaches that have been used to
examine associations between SES of individuals diagnosed with HIV/AIDS and their
survival and to systematically evaluate the existing evidence regarding the association
between socioeconomic gradients and patterns of HIV/AIDS mortality. Knowledge about
the role of SES on premature mortality of individuals with HIV/AIDS will facilitate the
tailoring of prevention programs to the needs of individuals and communities.
Materials and Methods
A comprehensive electronic search of published materials was conducted to identify
conceptual and empirical studies describing associations between the measures commonly
accepted in public health for evaluation of SES and survival of persons diagnosed with HIV/
AIDS. PubMed, National Library of Medicine Gateway of National Institutes of Health
(NLM), Social Science Citation Index, Wilson Web-Humanities and Social Sciences Index
Retrospective, FRANCIS (International Humanities and Social Studies), PsycINFO, and
CINAHL Plus were searched for abstracts and full text articles published in English and
other languages using the following combinations of keywords:’ HIV/AIDS, socio-
economic status, survival’, ‘HIV/AIDS, survival, SES’, ‘HIV/AIDS, mortality,
socioeconomic★’, ‘HIV/AIDS, mortality, socioeconomic index’, ‘HIV/AIDS, mortality,
socioeconomic deprivation’, ‘HIV/AIDS, mortality, socioeconomic position’, ‘HIV/AIDS,
mortality, economic status’, ‘HIV, mortality, neighborhood’, ‘HIV, mortality, education’,
‘HIV, mortality, income’, ‘HIV, mortality, social class’, ‘HIV, disease course★,
socioeconomic’, ‘HIV, mortality, deprivation index.’ Papers in English, Spanish, Italian, and
French were examined. In addition, the references of the retrieved publications were
reviewed as part of the search.
We included studies that met the following criteria: 1) measured AIDS-related deaths or all-
cause mortality among individuals infected with HIV; 2) reported original data; and 3)
analyzed SES as a predictor of mortality. The exclusion criteria were studies evaluating
effects of socio-economic and socio-cultural attributes on HIV/AIDS outcomes other than
AIDS-related or all-cause mortality, access to care, quality of life among HIV-infected
individuals, sexual behaviors, practices, and beliefs about HIV. Studies that documented
non-HIV/AIDSrelated deaths and accidental deaths among HIV-infected patients were
excluded from the review.
Retrieved publications were stratified by the study observation period because the
introduction of the effective therapeutic intervention of HAART in 1996 in the US, Canada,
Europe, and Latin American countries [4,34,35]. For the reports that studied cohorts until
1996, materials were considered as covering pre-HAART period (before introduction of
HAART), and for the evaluations where subjects were followed after 1996 published
research was assessed as encompassing post-HAART period (when HAART became widely
available). Further, we abstracted the key concepts used in the studies for SES assessments
and listed them according to the level (i.e. individual vs. community) of data collection
(Table1). We selected adjusted measures of association for the studies that reported both
crude and adjusted measures.
Using statistical software STATA version 10 (StataCorp LP, College Station, Texas), we
estimated the magnitude of the overall heterogeneity of the studies and the index of
heterogeneity after stratifying studies along various lines. We applied the methodology used
Pavlova-McCalla et al. Page 3
J AIDS Clin Res. Author manuscript; available in PMC 2014 February 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
by other investigators [36] to retain only the hazard ratios (HRs) and relative risks (RRs)
comparing lowest and highest categories when SES variables were defined in terms of
quintile or levels (e.g., level I,II,III,IV). If there was more than one socioeconomic variable,
we first analyzed socio-economic resource (SER) index or socio-economic index (SEI), if
present, because these are composite measures. If information on the index was not
available, income and poverty status were considered next and then employment status,
occupation, and education level. Income was chosen over education if both present, because
income is a realized resource and education allows potential access to the desired resources
[29]. However, studies of post-HAART period evaluating effects of higher SES versus low
(when different SES determinants were combined) showed that the variation in effect size
was 84.1 percent. The assessment of studies for pre-HAART period examining effects of
lower SES vs. high with combination of SES indicators produced similar findings.
Stratifications on a particular variable of SES (such as income, education level, SEI) were
performed, and these too demonstrated a statistically significant high level of heterogeneity.
After multiple stratifications, it became apparent that the degree of heterogeneity among
studies was too large to be explained and, therefore, a decision was made that meta-analysis
would not be conducted.
Literature Search
Of the 314 studies found using the keywords, 54 were deemed to be relevant (Figure 1).
Eight cross-sectional [37–44] and eight ecologic studies [45–52] were excluded from the
analysis because they examined absolute and relative differences in mortality risk for HIV/
AIDS according to the socioeconomic characteristics of the area of patients’ residence at the
time of AIDS diagnosis. Therefore, it was not possible to determine the extent of mortality
due to poor survival of people with HIV/AIDS versus differences in HIV incidence and
prevalence by socioeconomic group. Four publications were not considered for the analysis
because they provided insufficient survival analysis data [53–56].
One study was excluded because in comparison of survival probability among persons with
AIDS (PWA) at 24 months after AIDS diagnosis significant differences in the AIDS
incidence for low and high income levels were not adequately addressed [57]. This study
also reported mortality risk for the 2-year periods before and after introduction of HAART
with 1993–1995 period selected as reference mainly showing effects of HAART rather than
magnitude of the problem in relation to SES. Another was excluded because the excess
mortality in HIV-positive patients according to socio-demographic characteristics was
reported in relation to a HIV-negative cohort [58]. A Swiss study was excluded because it
evaluated social co-factors of HIV-non-progression but not mortality [59]. A cohort study on
mortality among HIV-infected participants in the Women’s Interagency HIV Study and the
Multicenter AIDS Cohort Study were excluded because it focused only on accident- and
injury-related deaths [60].
Three reports were eliminated because they combined death with clinical outcomes (e.g., all-
cause hospitalization and death/clinical progression) so it was not possible to separate the
effect of SES on death from other outcomes [61–63]. One report was excluded because of
concern that the outcome of hospital mortality and the measure of SES type of admission as
a proxy for individual SES would limit the generalizability of findings [64]. Concerns
regarding non-representativeness of the study sample lead us to exclude one US study that
explored relationships between crack use and HIV disease outcomes among women while
evaluating income and education as potential confounders [65]. Similarly, a Canadian report
examining effects of self-reported income on mortality among HIV-infected MSM and a
Spanish study evaluating role of education on mortality risk among HIV-infected IDUs were
removed from this review due to limitations involving the cohorts with one transmission
mode [66,67].
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Two studies done in African countries were excluded because of the generalizability
concerns arising when results are compared between “high” and “low” income countries and
when there is inadequate information on differentials regarding definitions of SES and
modifying effects of countries’ social contexts characterized by high levels of economic
inequality and limited access to HAART. The first of these studies, conducted in South
Africa, compared the hazards of all-cause death in treatment-naïve HIV-infected adults
initiating ART and having some monthly income versus no monthly income during one-year
follow-up [68]. It was not clear if the mortality was related to the earned income/government
disability grants or continuous access to health care and the disease stage when patients
became eligible for disability grants. The second study, carried out in Rwanda, was limited
to only ART-naïve HIV-positive women of childbearing age and found low household
income as a statistically significant independent predictor of mortality [69]. Thus, 21
publications of the period between 1992 and 2009 were included in the present review
(Table 1).
Results
Of the 21 studies included in this review, 14 originated from North America and seven from
Europe (Table 1). Four studies examined effects of SES on mortality with HIV/AIDS in the
years of pre-HAART period [70–73]. Fifteen studies provided an assessment of SES in
relation to survival in HIV-infected patients during the years of commercial availability of
HAART [74–88]. Two studies [34,35] evaluated the impact of SES on survival with HIV/
AIDS in both periods. Investigators used either patients’ self-report of the socioeconomic
determinants or linkage of the individuals’ residence at the time of diagnosis with the census
data. Understandably, cost and difficulties in obtaining individual SES data cause
researchers’ reliance on census data as a surrogate for SES assessment. However, studies
with the area-level of SES often failed to specify their conceptual approaches as to whether
the census data were applied as a proxy of individual SES or as an assessment of contextual
socioeconomic effect. There were no studies with multilevel SES measurements.
While efforts to operationalize SES continue to evolve, current SES assessment in relation
to health generally relies on data from occupational position, education, income, poverty
status, or any combination of these measures [29]. The present review of studies on the
relationship between SES and mortality risk among patients with HIV/AIDS confirmed the
consistency of this approach. Most of the studies included in the review used more than one
of the common determinants to measure SES. Nine reports [34,35,71,75,76,80,81,84,85]
presented one arbitrarily selected measure to quantify the association between SES and
mortality among people with HIV/AIDS. Education was the most frequently used measure
of SES followed by income, and employment status (Table 1). The most common rationale
for the selection of a particular socioeconomic measure in the reports was that it had been
adopted in the past and had high predictive validity. A calculated SES index was used in five
studies [34,71,79,82,88] because of a perception that a complex index discriminates better
than its components. Homelessness and access to health insurance or the type of health
insurance as a factor affecting survival with HIV/AIDS was considered only in the US
studies of post-HAART period indicating the importance of these variables in the pathways
between effective therapy initiation and survival.
Studies also differ in terms of studied population. Seven reports provided data on survival of
persons with AIDS (PWAs) only [34,71,72,79,80,85,88], one examined survival of HIV-
infected parents of adolescents [73], one looked at survival in HIV-infected children [78],
and the remaining studies assessed HIV-infected patients of both genders and various age
groups (Table 1). While the majority of retrieved publications looked at all-cause mortality
in individuals diagnosed with HIV/AIDS, two Canadian reports [75,83] and one US study
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[80] covering the post-HAART period described HIV/AIDS-related mortality. Crude HR or
RR of death was reported in eight studies and adjusted measures of association were found
in the remaining (Table1).
Studies of Pre-HAART Period
Four retrieved studies of pre-HAART period evaluated the risk for mortality in relation to
SES in samples of individuals with the range of mean ages from 22 to 39 years and the
range of median follow-up from 16.1 months to 28 months [70–73]. Significant association
between education and mortality in HIV-infected patients was found only in one US study
[73] which found that adults without a high school diploma were at a higher risk of death.
The same study found that perceived financial status (comfortable vs. very poor) was not
associated with mortality, but availability of social support significantly decreased risk of
death in the cohort of parents with adolescent children. While education partly serves as an
indicator of social capital, the key factor of material capital, income, did not affect mortality
in a large population of HIV-infected patients with different transmission modes [70].
However, in the same study, an indicator of human capital, employment status at baseline,
was a statistically significant protective factor for mortality with HIV/AIDS in crude
analysis [70].
One Italian study calculated a composite socioeconomic measure including variables of
income and social support and did not find statistically significant effects of socioeconomic
resource index (SER) on mortality among PWA [71]. These results were consistent with the
findings of the only study of the pre-HAART period that adjusted the measure of association
for demographic and clinical variables. Using census block group-level socioeconomic data,
this study did not find statistically significant association between mortality in persons
diagnosed with AIDS and living in a neighborhood characterized by poverty, working class
occupation, or low educational level [72].
Studies of post-HAART period
Included in the review, 15 reports of post-HAART period examined relationships between
SES and all-cause mortality and HIV/AIDS-related mortality among HIV-infected patients
with the mean age ranging from 11 to 42.5 years and the median follow-up ranging from 12
months to 8.6 years [74–88]. The composite index of one of these studies was based on the
variables of availability of stable income, owned residential property, the need to receive
social support, and the effective availability of this support in the past and at the time of
interview [82]. Measured by this index, low SES significantly increased mortality risk of
individuals diagnosed with HIV after adjustments for clinical variables [82]. In contrast,
SES measured at area-level by a composite index was not associated with increased
mortality in PWAs after adjustments for demographic and clinical variables, stage of the
disease, and ART initiation [79,88].
Low household income was a significant predictor of mortality among patients with HIV/
AIDS in three Canadian studies, a setting with universal access to health care [75,83,86].
However, one study with individually collected SES data did not find an association
between income and HIV/AIDS mortality risk [77]. The lack of such association was
supported in two reports that applied area-level of SES data: a US study evaluating
unadjusted risk of death in HIV-infected patients [87] and an Italian study examining
mortality among PWA after adjustments for relevant variables [79]. Only one US study
assessed wealth. Selfreported lack of accumulated assets in the population-based sample of
people with HIV/AIDS was associated with statistically significant increased risk for all-
cause and HIV-related mortality even after adjustments for sociodemographic, clinical, and
treatment variables [77].
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Five studies carried out in different countries indicated that education beyond a high school
degree was a statistically significant protective factor for all-cause and HIV/AIDS-related
mortality [77,78,82,83,86], and one report showed no significant association with education
[87]. Poverty as the area-level SES factor was positively associated with an increased risk of
death in HIV-infected patients even after adjustments for age, clinical and treatment
variables [83,84]. The only study that examined the effect of social context on survival of
HIV-infected children found that maternal unemployment was associated with lower
survival after adjustment for baseline AIDS diagnosis [78]. Lack of employment, an
important dimension of maternal, social, and human capital, was found to be associated with
an increased risk for HIV/AIDS mortality in four other studies applying this measure after
adjusting for demographic, clinical and treatments factors [77,81,83,86].
The effects of social capital indicators were also significant. Stable partnership was a
protective factor for mortality in a Swiss cohort of HIV-infected patients after adjustments
for education, ART, demographic and clinical variables [76]. Living situation characterized
by unmarried status and not living with a partner was a significant predictor of mortality in a
case-control study [74]. The same case-control study demonstrated that homelessness
increased the risk of death in patients with HIV, but the association was not assessed for
potential confounders. Another US study using an adjusted measure of association between
homelessness and HIV/AIDS mortality risk found no statistically significant association
[77].
Six studies used type of insurance as the measure for SES. An earlier publication of the post-
HAART period showed that HIV-infected patients receiving care from Medicaid were at a
higher risk of death compared with those in care under provisions of Ryan White Act [74].
Lack of insurance after adjustment for sociodemographic and clinical variables was also
associated with a reduced relative risk of death as compared with having private insurance in
a cohort of persons diagnosed with HIV/AIDS [77]. Recent studies, however, indicated that
lack of health insurance or having Medicaid or Medicare compared with private insurance
increased the risk of death [80,85,87,88]. However, adjustments for the patients’ age and the
disease stage were found only in two studies [80,85]. Such adjustment of the measure of
association is important because Medicare eligibility is based on age or disability status and
it would be expected that people receiving Medicare would be at higher risk of death due to
the facts of being older or with more advanced disease.
Studies comparing pre- and post-HAART periods
Two reports compared mortality among persons diagnosed with HIV/AIDS before and after
introduction of HAART based on area-level of SES. For both periods, no association was
found in a San Francisco study between neighborhood median household income and risk of
mortality in HIV-infected patients after adjustment for relevant variables including use of
HAART [35]. However, an Italian study assessing SES by composite index indicated that in
the post-HAART period, living in a deprived area increased risk of death among PWA after
adjustment for a set of variables but not HAART use [34]. In addition to the use of various
dimensions of SES, the presentation of crude measures of association, and analysis of
different arrays of potential confounders allowed us to conclude that interpretation and
evaluation of the results of the studies included in this review largely depend on the
researchers’ conceptual approach.
Discussion
Socioeconomic factors have been examined and postulated as an explanation for
unfavorable health outcomes and excess burden of chronic diseases [89,90]. However, the
direction and strength of the relationship between SES and health status depend on how SES
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is defined, the outcome of interest, the demographic composition of the cohorts, and the
geographic regions under studies [91]. Our review confirmed that heterogeneity of available
research investigating relationship between SES and mortality risk among HIV-infected
individuals preclude making definite conclusions whether SES is an independent predictor
of mortality in people diagnosed with HIV/AIDS or a modifying factor for HIV progression
to death. This is the first review evaluating studies about the association between SES and
mortality among people with HIV/AIDS for the periods before and after introduction of
HAART. A more uniform conceptualization of the socioeconomic status both at the
individual and neighborhood levels with regards to HIV is needed to better understand the
role of SES on mortality of people diagnosed with HIV/AIDS.
The results of the review revealed that six studies observing subjects’ survival in the pre-
HAART period (including the two studies covering both periods) [34,35,70–73] did not find
a statistically significant association between mortality risk and low income [35,70], poor
financial status [73], poverty [72], or living in a neighborhood characterized by low SES
[34], and higher percent of working class population [72]. While work is the major structural
link between education and income or material condition, only one report of pre-HAART
period demonstrated protective effects of employment at baseline for mortality with HIV/
AIDS [70]. Conflicting results regarding effects of education on mortality of HIV-infected
patients [70,73] supported the notion that educational achievement at the individual level
does not allow to trace the relationship with health because education has different social
meaning and consequences in different times and settings [92]. In addition to variations of
SES measurements, the lack of the clear effect of SES on mortality risk was likely due to the
limited effectiveness of HIV treatment in the pre-HAART period and thus factors linking
SES to mortality through the ability to access and negotiate health care would not have
greatly influenced survival.
On the other hand, the studies of post-HAART period generally showed greater all-cause
mortality and HIV/AIDS-related mortality risk for people living in neighborhoods
characterized by low socioeconomic index [34,82], low income [75,83,86], and high levels
of poverty [84]. However, this association was not statistically significant in most of the
studies where adjustments of the mortality risk were made for HAART use [35,77,88],
suggesting that the observed advantage conferred by being high SES may be at least partly
related to having better access to treatment. While four out of seven papers of post-HAART
period did not find increased mortality risk for people with low income [55,77,79,87] four
out of five studies examining effects of education showed that higher educational
achievement was protective [77,82,83,86].
These findings are somewhat expected, since once more effective treatment becomes
available, access to care can make a difference in survival and tends to be higher for those of
higher SES. Thus, SES may exhibit modifying effects on HIV/AIDS outcomes. To bring
more clarity to the role of SES on mortality with HIV/AIDS, the measures of SES should be
considered in the life course perspective. All studies included in the review measured SES at
one time, usually adulthood. This limits understanding about how SES at individual or
neighborhood-level affects HIV progression to death when patients with HIV/AIDS are not
able to work and live on disability allowance, but may have higher levels of education or
social support available. Reverse causation between income, employment status, and health
outcomes cannot be excluded. Furthermore, socioeconomic indicators interrelate and the
difficulty of understanding what factor comes first or has larger impact on survival have
been noted in other epidemiologic studies and systematic reviews [36,89]. Studies included
in the present review did not take into account the hierarchical structure of socioeconomic
indicators in terms of importance and impact degree in their data analysis.
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The findings that employment at baseline significantly decreased mortality risk with HIV/
AIDS before and after the introduction of HAART may reflect better baseline health among
patients who were able to work. The importance of clinical staging in the analysis of
survival with HIV/AIDS cannot be overstressed. People are diagnosed at different times of
their disease course and socioeconomic gradients may serve as markers of the disease
staging. The evidence that even in universal health care settings unemployment at baseline
was highly predictive for delayed access to treatment [83] may indicate patients’ inability to
work due to poor health at the time of presentation for HIV care. The fact that having private
insurance decreased mortality in HIV-infected individuals [80,85–88] can be a marker of
better health and an earlier stage of the disease when people are able to work and thus are
eligible for private insurance, and have not exhausted their financial resources or insurance
limits.
Fifteen of the 21 studies adjusted for one or more clinical variables at the time of diagnosis.
AIDS diagnosis and CD4 cell counts point out HIV progression and, therefore, they should
always be adjusted for in the survival analysis if available. In the post-HAART period,
treatment variables, such as access to care and HAART adherence [18,93,94] affecting
disease progression must be considered along with clinical variables in relation to the
patients’ SES. The recent trend of an increasing proportion of older adults with more
advanced HIV disease compared to younger individuals at first presentation for care [13,16]
also highlights the importance of adjusting measures of association for age and AIDS
diagnosis in the analysis of the effects of SES on mortality and morbidity due to HIV/AIDS.
There is also a relationship between mode of HIV transmission and risk of HIV progression
to AIDS and death. Persons with different risk factors (e.g. injection drug use) may have
therapy adherence problems due to their behavioral and decision-making characteristics that
may have grounds in low education, low incomes, unemployment, and low occupational
status [18]. It has been documented that the relative survival estimates by transmission
category are significantly better for males exposed through male-to-male sexual contact as
compared with other transmission groups [84]. In MSM, the disease progression may take
longer time as compared with IDUs [95]. However, other studies did not confirm these
findings [72,96]. HIV-infected patients who stop injecting drugs can have a reduced risk of
disease progression when compared with current users [73]. In the three papers [34,35,79]
that included demographic information about their studied population by the transmission
factor, MSM transmission mode was associated with a higher SES level while IDU was
associated with a lower SES level. Thus, differentials of mortality according to SES levels
may have been due to variations of disease progression in persons with different HIV risk
factors.
Most of the studies measuring SES at the community level did not explicitly state if they
considered the community level SES as proxies for individual SES or as measures of the
social setting quality in which the HIV-infected person lives. This is important because
designing intervention programs often involves targeting specific populations or addressing
community needs. For instance, in the cases of employment status measured at the
individual level, unemployment may mean that the person has no marketable skills, is too
sick to work, or work is not available in his/her community. In contrast, unemployment on
the area-based level can indicate a loss of social support in the community due to a difficult
economic situation. Ideally, multilevel studies, which measure subjects’ SES at individual
and community level, should be conducted to elucidate the pathways between social
determinants and HIV survival. At a minimum, reporting results of studies that use area-
based SES variables should explicitly state whether the measurements are meant to be
proxies for individual SES level or measures of the social environment in which the
individual lives [31].
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Although there is a clear need for the development and validation of a measure of SES that
is appropriate for studying HIV survival, the available evidence suggests that SES is not
consistently and strongly associated with all-cause and disease-specific mortality risk of
HIV-infected patients when access to antiretroviral therapy is considered. The synthesis of
the available up-to-date knowledge on the association between SES and mortality risk
among people with HIV/AIDS indicates that SES affects patients’ survival to a different
extent in various population groups at distinctive points of disease progression. The effects
of SES on mortality due to HIV/AIDS are also likely through modifying other factors
relating to disease progression, especially in the post-HAART period. Further population-
based studies with clearer conceptualization of SES and preferably multilevel measurements
are needed to enhance understanding of the role of socioeconomic gradients on HIV
outcomes. Improved understanding of the relationship between socioeconomic
disadvantages and outcomes of such life-threatening infection will provide necessary
information for designing and tailoring of public health programs for specific population
groups at higher risk for HIV progression and address the effects of SES on health in order
to reduce mortality and avert potential years of life lost.
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Figure 1.
Study selection process in a literature review of the relation between SES and survival of
individuals with HIV/AIDS.
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